Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer.
Fan YangChenyang YuanFanghui ChenZhaohui S QinNicole C SchmittGregory B LesinskiNabil F SabaYong TengPublished in: Journal of experimental & clinical cancer research : CR (2024)
These findings demonstrate that dual blockade of IL6 and CCR2 pathways effectively enhances the antitumor activity of NK cells in HPV-negative HNSCC, providing a novel strategy for treating this type of cancer.